Pariglasgene brecaparvovec
Gene therapyexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jul 24, 2018 (NCT03517085)
Timeline
Indications
Mechanism of action
- Glucose-6-phosphataseSupplementation
G6PC1 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095444 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05139316 | Phase 3 | Nov 30, 2021 | Ultragenyx Inc. |
| NCT03517085 | Phase 1/Phase 2 (Phase 2) | Jul 24, 2018 | Ultragenyx Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ultragenyx Inc. | For profit | 2 | 2 | 2 | 2018 |
1 organizations
Page 1 / 1